Ticker

Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,847 shares of the business's stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $10.42 per share, with a total value of $5,000,005.74. Following the completion of the transaction, the director owned 1,979,847 shares of

Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH103, leveraging unique molecular engineering for improved efficacy and durability. KLRS's Phase 1a data showed a clinically significant 10-letter visual acuity gain and promising durability, with 31% of patients needing no rescue injection for six months. With $77M in cash and a quarterly burn of ~$12M, KLRS is funded…

Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS's lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26.

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private…

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection